Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Many people confuse metformin with GLP-1 medications because both address blood sugar and weight, but they work through completely different biological pathways. Metformin is an older insulin-sensitizing drug developed in the 1950s, while GLP-1 agonists like semaglutide are newer hormonal therapies that activate specific intestinal receptors. Knowing which medication targets your individual metabolism is essential for effective treatment.
What Is Metformin and How Does It Work?
Metformin is an oral medication in the biguanide drug class, originally derived from French lilac plant compounds. It lowers blood glucose by reducing the amount of glucose your liver makes and improves how your muscles use insulin, a process called insulin sensitization. Metformin does not directly stimulate insulin release and has been a first-line diabetes treatment for over 50 years.
This medication typically reduces fasting blood glucose by 25–30 mg/dL and A1C levels by about 1.5% when used alone. Metformin does cause modest weight loss—usually 2–3 pounds over months—as a side effect rather than its primary action. It carries minimal hypoglycemia risk when used without other glucose-lowering drugs, making it one of the safest glucose-management options available.
What Are GLP-1 Agonists and Their Mechanism?
GLP-1 (glucagon-like peptide-1) receptor agonists are a newer class of medications that mimic a natural hormone your intestines release after eating. These drugs activate GLP-1 receptors throughout your body—in the pancreas, brain, and gut—triggering multiple metabolic changes simultaneously. Unlike metformin's insulin-sensitizing approach, GLP-1 agonists work by increasing insulin secretion, slowing stomach emptying, and signaling fullness to your brain's appetite centers.
Semaglutide, the GLP-1 agonist featured in PlexusDx's compounded injection therapy, produces weight loss of 15–22% of body weight in clinical studies—dramatically more than metformin. This medication reduces appetite at the neurological level and improves cardiovascular outcomes in people with type 2 diabetes, effects metformin alone does not achieve. GLP-1 agonists represent a fundamental shift from glucose management toward whole-body metabolic rebalancing.
Key Differences: Metformin vs. GLP-1 Medications
The primary difference lies in mechanism: metformin makes your existing insulin work better, while GLP-1 agonists make your pancreas secrete more insulin and suppress your appetite through brain-level signaling. Metformin has been available since the 1950s with a decades-long safety record, whereas GLP-1 drugs were developed starting in the early 2000s and continue to show new benefits in ongoing research. Weight loss results differ dramatically—metformin achieves modest loss of a few pounds, while semaglutide typically produces 30–50+ pounds of weight reduction depending on your baseline and adherence.
Cost and administration also differ significantly. Metformin is a low-cost oral pill taken twice daily with meals, costing pennies per dose. PlexusDx's compounded semaglutide injection starts at $149 per month with no insurance required and is administered once weekly, offering a modern convenience factor that oral metformin lacks. Both are HSA/FSA eligible, but semaglutide's mechanism makes it far more effective for meaningful weight loss outcomes.
Should You Choose Metformin or GLP-1 Therapy?
Your choice depends on your treatment goals, starting weight, and metabolic profile. If you have mild insulin resistance without significant obesity and want to reduce medication burden, metformin remains a solid foundational option. However, if your primary goal is substantial weight loss, improved cardiovascular health, or you've had limited success with diet and lifestyle alone, a GLP-1 agonist like PlexusDx's semaglutide injection offers superior clinical outcomes backed by large-scale trials.
PlexusDx's Precision Peptide Genetic Test—a $99 add-on after your first month of treatment—maps 14 metabolic pathways and 49 peptide responses to help personalize whether GLP-1 therapy, combination approaches, or other mechanisms are optimal for your genetic makeup. Your genetic variants in GLP1R, GIPR, FTO, and MC4R pathways can predict your individual response to semaglutide versus other options. This precision approach removes guesswork and aligns medication selection with your biology rather than a one-size-fits-all assumption.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is metformin a type of GLP-1 medication?
No. Metformin is a biguanide that improves insulin sensitivity, while GLP-1 agonists are a separate hormonal drug class that activate GLP-1 receptors and trigger appetite suppression. They work through different biological mechanisms and are not interchangeable.
Which causes more weight loss—metformin or semaglutide?
Semaglutide produces significantly greater weight loss: 15–22% of body weight in clinical trials versus 2–3 pounds with metformin. PlexusDx's compounded semaglutide injection starts at $149/mo and delivers this superior outcome without flat per-compound pricing increases.
Can I take metformin and GLP-1 together?
Yes, many patients benefit from combining metformin (for insulin sensitization) with GLP-1 agonists (for appetite suppression and additional glucose control). Your prescribing provider can determine if this combination aligns with your metabolic needs and treatment goals.
What are the side effects of each medication?
Metformin commonly causes gastrointestinal upset and vitamin B12 depletion with long-term use. GLP-1 agonists like semaglutide produce nausea (usually mild and temporary), constipation, and rare pancreatitis signals—but side effects typically diminish as your body adjusts over weeks.
How does the PlexusDx Precision Peptide Genetic Test help choose between them?
The test analyzes your genetic variants in GLP1R, GIPR, FTO, and MC4R pathways—mapping 150+ insights across 49 peptides—to predict your individual response to GLP-1 therapy versus other mechanisms. This data-driven approach ensures you receive the medication most likely to work for your unique biology rather than trial-and-error prescribing.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can I Eat After Semaglutide Injection?
A Detailed Guide on Exactly Where to Give Ozempic Shot in Thigh for Best Results